-
Mashup Score: 2
Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Two drugs for the treatment of metastatic urothelial carcinoma—eftilagimod alpha and avelumab—will be examined in the phase 1 INSIGHT-005 clinical trial.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Deep and durable responses were seen with #pembrolizumab in combination with #eftilagimod alpha in patients with advanced non–small cell lung cancer, according to the phase 2 TACTI-002 trial findings. #NSCLC #lcsm #SITC22 | @VUMC_Cancer @VUMChealth https://t.co/3hohZnA2FY